Vanda Pharmaceuticals Inc.
VNDA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $56,258 | $52,590 | $50,041 | $53,185 |
| % Growth | 7% | 5.1% | -5.9% | – |
| Cost of Goods Sold | $2,954 | $4,487 | $3,521 | $2,590 |
| Gross Profit | $53,304 | $48,103 | $46,520 | $50,595 |
| % Margin | 94.7% | 91.5% | 93% | 95.1% |
| R&D Expenses | $22,563 | $21,990 | $35,712 | $19,840 |
| G&A Expenses | $0 | $0 | $0 | $37,382 |
| SG&A Expenses | $60,273 | $64,616 | $50,084 | $39,282 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $1,900 |
| Other Operating Expenses | $1,752 | $0 | $5,273 | $1,752 |
| Operating Expenses | $84,588 | $86,606 | $91,069 | $60,874 |
| Operating Income | -$31,284 | -$38,503 | -$44,549 | -$10,279 |
| % Margin | -55.6% | -73.2% | -89% | -19.3% |
| Other Income/Exp. Net | $2,894 | $3,616 | $7,181 | $3,782 |
| Pre-Tax Income | -$28,390 | -$34,887 | -$37,368 | -$6,497 |
| Tax Expense | -$5,804 | -$7,680 | -$7,874 | -$1,585 |
| Net Income | -$22,586 | -$27,207 | -$29,494 | -$4,912 |
| % Margin | -40.1% | -51.7% | -58.9% | -9.2% |
| EPS | -0.38 | -0.46 | -0.5 | -0.085 |
| % Growth | 17.4% | 8% | -491.7% | – |
| EPS Diluted | -0.38 | -0.46 | -0.5 | -0.085 |
| Weighted Avg Shares Out | 58,873 | 58,994 | 58,528 | 58,308 |
| Weighted Avg Shares Out Dil | 58,873 | 58,994 | 58,528 | 58,308 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2,053 | $2,018 | $980 | $1,973 |
| EBITDA | -$29,231 | -$32,869 | -$31,115 | -$8,306 |
| % Margin | -52% | -62.5% | -62.2% | -15.6% |